Lung Clinical Trials
Delivering quality care through clinical trials
AstraZeneca - D702GC00001 - (ARTEMIDE-Lung04)
Study Phase: Phase III
Condition(s): Stage IV Non-Small Cell Lung Cancer, PD-L1 high
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)
ClinicalTrials.gov NCT ID: NCT06868277
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
BioNTech BNT327-03
Study Phase: Phase III
Condition(s): Extensive Stage Small Cell Lung Cancer
A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first line extensive-stage small-cell lung cancer
ClinicalTrials.gov NCT ID: NCT06712355
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
Merck MK2870-023
Study Phase: Phase III - Drug
Condition(s): Stage IV squamous NSCLC
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab with or without Maintenance MK2870 in the First-line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer
ClinicalTrials.gov NCT ID: NCT06422143
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
Merck V940-009
Study Phase: Phase III - Drug
Condition(s): Stage II - IIIB NSCLC
Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab with or without V940 in Resectable Stages II-IIIB(N2) NSCLC for patients not achieving pCR after receiving Neoadjuvant Pembrolizumab with chemotherapy followed by surgery
ClinicalTrials.gov NCT ID: NCT06623422
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
NRG - NRG-LU007
Study Phase: Phase II/III - Drug
Condition(s): Extensive stage small cell lung cancer
Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
ClinicalTrials.gov NCT ID: NCT04402788
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
OncoC4 PRESERVE-03
Study Phase: Phase III
Condition(s): Metastatic Squamous Non-Small Cell Lung Cancer
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors
ClinicalTrials.gov NCT ID: NCT05671510
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
To inquire if you're eligible for a clinical trial, contact: (484) 658-5080, or click here to complete a clinical trial inquiry form.
